Medigen Biotechnology Statistics
Total Valuation
Medigen Biotechnology has a market cap or net worth of TWD 4.97 billion. The enterprise value is 6.79 billion.
Market Cap | 4.97B |
Enterprise Value | 6.79B |
Important Dates
The next estimated earnings date is Tuesday, November 12, 2024.
Earnings Date | Nov 12, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Medigen Biotechnology has 139.23 million shares outstanding. The number of shares has increased by 0.17% in one year.
Shares Outstanding | 139.23M |
Shares Change (YoY) | +0.17% |
Shares Change (QoQ) | +0.05% |
Owned by Insiders (%) | 6.56% |
Owned by Institutions (%) | 4.26% |
Float | 109.13M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 3.57 |
PB Ratio | 2.97 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -15.67 |
EV / Sales | 4.87 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -30.72 |
Financial Position
The company has a current ratio of 3.60, with a Debt / Equity ratio of 19.74.
Current Ratio | 3.60 |
Quick Ratio | 2.92 |
Debt / Equity | 19.74 |
Debt / EBITDA | n/a |
Debt / FCF | -4.55 |
Interest Coverage | -15.26 |
Financial Efficiency
Return on equity (ROE) is -17.58% and return on invested capital (ROIC) is -6.84%.
Return on Equity (ROE) | -17.58% |
Return on Assets (ROA) | -6.29% |
Return on Capital (ROIC) | -6.84% |
Revenue Per Employee | n/a |
Profits Per Employee | n/a |
Employee Count | n/a |
Asset Turnover | 0.17 |
Inventory Turnover | 0.72 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +6.23% in the last 52 weeks. The beta is 0.57, so Medigen Biotechnology's price volatility has been lower than the market average.
Beta (5Y) | 0.57 |
52-Week Price Change | +6.23% |
50-Day Moving Average | 39.08 |
200-Day Moving Average | 41.72 |
Relative Strength Index (RSI) | 29.72 |
Average Volume (20 Days) | 101,478 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Medigen Biotechnology had revenue of TWD 1.39 billion and -433.07 million in losses. Loss per share was -3.11.
Revenue | 1.39B |
Gross Profit | 791.99M |
Operating Income | -807.12M |
Pretax Income | -764.54M |
Net Income | -433.07M |
EBITDA | -655.04M |
EBIT | -807.12M |
Loss Per Share | -3.11 |
Balance Sheet
The company has 2.60 billion in cash and 1.00 billion in debt, giving a net cash position of 1.60 billion or 11.47 per share.
Cash & Cash Equivalents | 2.60B |
Total Debt | 1.00B |
Net Cash | 1.60B |
Net Cash Per Share | 11.47 |
Equity (Book Value) | 5.09B |
Book Value Per Share | 12.03 |
Working Capital | 2.70B |
Cash Flow
In the last 12 months, operating cash flow was -183.10 million and capital expenditures -37.85 million, giving a free cash flow of -220.95 million.
Operating Cash Flow | -183.10M |
Capital Expenditures | -37.85M |
Free Cash Flow | -220.95M |
FCF Per Share | -1.59 |
Margins
Gross margin is 56.84%, with operating and profit margins of -57.93% and -31.08%.
Gross Margin | 56.84% |
Operating Margin | -57.93% |
Pretax Margin | -54.87% |
Profit Margin | -31.08% |
EBITDA Margin | -47.01% |
EBIT Margin | -57.93% |
FCF Margin | -15.86% |
Dividends & Yields
Medigen Biotechnology does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -0.17% |
Shareholder Yield | -0.17% |
Earnings Yield | -8.71% |
FCF Yield | -4.45% |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |